Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NBIX said that in a double-blind, placebo-controlled U.S. Phase II study in 79 patients (ages 65-75)
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury